Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melanie Hopkins

Physician Assistant, Medical Lisbon, CT Physician Assistant

NPI 1528060845 CMS profile 11063980

2 Lee Rd, Lisbon, CT 06351

Open in the dashboard

General payments

$6,488

392 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melanie Hopkins of Lisbon, CT is reported in the CMS Open Payments database as having received $6,488 across 392 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,237 65
2024 General $1,465 83
2023 General $1,344 89
2022 General $1,247 79
2021 General $1,196 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melanie Hopkins
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Melanie Hopkins were reported at $1,237. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Melanie Hopkins Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,196 $156 $41–$563 $132
2022 $1,247 $185 $55–$649 $149
2023 $1,344 $199 $58–$717 $160
2024 $1,465 $206 $62–$740 $164
2025 $1,237 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,864 120 payments
  2. Novo Nordisk Inc $1,045 80 payments
  3. GlaxoSmithKline, LLC. $732 41 payments
  4. AstraZeneca Pharmaceuticals LP $386 20 payments
  5. Otsuka America Pharmaceutical, Inc. $341 19 payments
  6. Phathom Pharmaceuticals, Inc. $311 16 payments
  7. Astellas Pharma US Inc $297 14 payments
  8. Pfizer Inc. $279 15 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $225 12 payments
  10. Amgen Inc. $191 11 payments
  11. Other $816 44 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,488 392 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,018 79 payments
  2. RYBELSUS $985 77 payments
  3. VRAYLAR $733 59 payments
  4. UBRELVY $729 36 payments
  5. TRELEGY ELLIPTA $535 30 payments
  6. REXULTI Psychiatry $341 19 payments
  7. QULIPTA $334 20 payments
  8. MYRBETRIQ $194 10 payments
  9. Otezla $191 11 payments
  10. REXULTI Psychiatry $175 8 payments
  11. Other $2,846 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 123 drugs

Part D claims

6,571

Median for Physician Assistant: 241

Drug cost

$399,118

Median for Physician Assistant: $4,110

Branded share of claims

18.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 98 $128,706
Januvia Sitagliptin Phosphate Brand 32 $36,642
Eliquis Apixaban Brand 24 $29,569
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $28,630
Farxiga Dapagliflozin Propanediol Brand 13 $21,807
Myrbetriq Mirabegron Brand 24 $15,286
Jardiance Empagliflozin Brand 18 $14,978
Butalb-Acetaminoph-Caff-Codein Butalbit/Acetamin/Caff/Codeine Brand 14 $10,385
Breo Ellipta Fluticasone/Vilanterol Brand 14 $9,679
Dexlansoprazole Dr Dexlansoprazole Brand 26 $7,815

The 10 drugs with the highest cost, of 123 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$39,786

Of which drugs: $262

Medicare patients

165

Average age 75

Services billed

488

122 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 38%
Diabetes 21%
COPD 21%
Ischemic heart disease 20%
Atrial fibrillation 20%
Cancer 20%
Chronic kidney disease 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $157
$157 — —
VRAYLAR
  • AbbVie, Inc. $146
$146 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $106
$106 32 —
RYBELSUS
  • Novo Nordisk Inc $103
$103 — —
Ozempic
  • Novo Nordisk Inc $103
$103 98 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

392 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record